Skip to content

A verification study of safety evaluation of excessive ingestion of NMN-containing food in humans: a randomized, double-blind, placebo-controlled, parallel study

A verification study of safety evaluation of excessive ingestion of NMN-containing food in humans: a randomized, double-blind, placebo-controlled, parallel study - Safety evaluation of excess ingestion of NMN-containing food in humans.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000043084
Enrollment
32
Registered
2021-01-27
Start date
2021-01-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Intake of NMN-containing food once a day for 4 weeks. Intake of placebo without NMN once a day for 4 weeks.

Sponsors

Pharma Foods International Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Males and females, aged 20 - 65 years old. 2)Subjects who are deagnosed as eligible to participate in the study by the physician

Exclusion criteria

Exclusion criteria: 1)A medical history of malignant tumor, heart failure or myocardial infarction. 2) Currently undergoing treatment for any of the following chronic diseases: atrial fibrillation, cardiac arrhythmia, liver failure, kidney failure, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 3) Subjects who currently taking medications (including herbal medicines) 4) Subjects who are allergic to medications and/or the test food related products. 5) Subjects who are pregnant, breast-feeding, or planning to become pregnant. 6) Subjects who are judged as ineligible to participate in the study by the physician.

Design outcomes

Primary

MeasureTime frame
1. Physical examination 2. Urinalysis 3. Blood test * Assess these tests at screening (before consumption) and at 2 and 4 weeks after consumption and 2 weeks after consumption completed.

Countries

Japan

Contacts

Public ContactAkiko Ishida

Pharma Foods International Co., Ltd. Research and Development Department 2

a-ishida@pharmafoods.co.jp075-748-9829

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026